{"doi":"10.1016/j.ijid.2022.12.039","title":"Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia","abstract":null,"journal":"International Journal of Infectious Diseases","year":2023,"id":630301,"datarank":0.4493598410330987,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.0,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1632755,"name":"Shu Okugawa","orcid":"0000-0003-3455-8291","position":1,"is_corresponding":false},{"id":1537729,"name":"Kosuke Kashiwabara","orcid":null,"position":2,"is_corresponding":false},{"id":1632759,"name":"Takashi Moritoyo","orcid":null,"position":3,"is_corresponding":false},{"id":1533582,"name":"Yoshiaki Kanno","orcid":null,"position":4,"is_corresponding":false},{"id":1632761,"name":"Daisuke Jubishi","orcid":null,"position":5,"is_corresponding":false},{"id":1632764,"name":"Hideki Hashimoto","orcid":null,"position":6,"is_corresponding":false},{"id":329860,"name":"Koh Okamoto","orcid":"0000-0002-4072-9096","position":7,"is_corresponding":false},{"id":1632766,"name":"Kenji Tsushima","orcid":null,"position":8,"is_corresponding":false},{"id":1304377,"name":"Yasuki Uchida","orcid":"0000-0002-1999-4709","position":9,"is_corresponding":false},{"id":1632768,"name":"Takahiro Mitsumura","orcid":null,"position":10,"is_corresponding":false},{"id":1228284,"name":"Hidetoshi Igari","orcid":"0000-0001-7754-3458","position":11,"is_corresponding":false},{"id":840231,"name":"Takeya Tsutsumi","orcid":"0000-0003-0851-1887","position":12,"is_corresponding":false},{"id":1632769,"name":"Hideki Araoka","orcid":null,"position":13,"is_corresponding":false},{"id":1606197,"name":"Kazuhiro Yatera","orcid":"0000-0002-2955-4432","position":14,"is_corresponding":false},{"id":1632770,"name":"Yoshihiro Yamamoto","orcid":"0000-0003-2088-8724","position":15,"is_corresponding":false},{"id":888294,"name":"Yuki Nakamura","orcid":"0000-0002-7730-0090","position":16,"is_corresponding":false},{"id":1156638,"name":"Amato Otani","orcid":"0009-0002-0191-8895","position":17,"is_corresponding":false},{"id":1632771,"name":"Marie Yamashita","orcid":null,"position":18,"is_corresponding":false},{"id":1632772,"name":"Yuji Wakimoto","orcid":null,"position":19,"is_corresponding":false},{"id":1632773,"name":"Takayuki Shinohara","orcid":"0000-0001-8804-0645","position":20,"is_corresponding":false},{"id":1632774,"name":"Maho Adachi-Katayama","orcid":"0000-0001-8960-8212","position":21,"is_corresponding":false},{"id":1632775,"name":"Tatsunori Oyabu","orcid":null,"position":22,"is_corresponding":false},{"id":1632777,"name":"Aoi Kanematsu","orcid":null,"position":23,"is_corresponding":false},{"id":1323174,"name":"Sohei Harada","orcid":"0000-0003-3073-6564","position":24,"is_corresponding":false},{"id":1632781,"name":"Yuichiro Takeshita","orcid":"0000-0001-7829-8968","position":25,"is_corresponding":false},{"id":1304380,"name":"Yasutaka Nakano","orcid":"0000-0001-7516-8690","position":26,"is_corresponding":false},{"id":1469296,"name":"Yasunari Miyazaki","orcid":"0000-0002-9073-9815","position":27,"is_corresponding":false},{"id":1549504,"name":"Seiichiro Sakao","orcid":null,"position":28,"is_corresponding":false},{"id":641890,"name":"Makoto Saito","orcid":"0000-0002-1667-9287","position":29,"is_corresponding":false},{"id":1632783,"name":"Sho Ogura","orcid":null,"position":30,"is_corresponding":false},{"id":1632784,"name":"Kei Yamasaki","orcid":null,"position":31,"is_corresponding":false},{"id":1632785,"name":"Hitoshi Kawasuji","orcid":"0000-0002-5536-101X","position":32,"is_corresponding":false},{"id":1632786,"name":"Osamu Hataji","orcid":null,"position":33,"is_corresponding":false},{"id":1632787,"name":"Jun-Ichiro Inoue","orcid":null,"position":34,"is_corresponding":false},{"id":1632788,"name":"Yasuyuki Seto","orcid":null,"position":35,"is_corresponding":false},{"id":409571,"name":"Kyoji Moriya","orcid":"0000-0001-9628-2724","position":36,"is_corresponding":false},{"id":1632753,"name":"Mahoko Ikeda","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia","abstract":"Objectives To evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19. Methods We conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patients with mild-to-moderate COVID-19 pneumonia. Patients were randomly assigned to receive favipiravir alone (n = 24) or nafamostat with favipiravir (n = 21). The outcomes included changes in the World Health Organization clinical progression scale score, time to improvement in body temperature, and improvement in oxygen saturation (SpO 2 ). Results There was no significant difference in the changes in the clinical progression scale between nafamostat with favipiravir and favipiravir alone groups (median, -0.444 vs -0.150, respectively; least-squares mean difference, -0.294; P = 0.364). The time to improvement in body temperature was significantly shorter in the combination group (5.0 days; 95% confidence interval, 4.0-7.0) than in the favipiravir group (9.0 days; 95% confidence interval, 7.0-18.0; P =0.009). The changes in SpO 2 were greater in the combination group than in the favipiravir group (0.526% vs -1.304%, respectively; least-squares mean difference, 1.831; P = 0.022). No serious adverse events or deaths were reported, but phlebitis occurred in 57.1% of the patients in the combination group. Conclusion Although our study showed no differences in clinical progression, earlier defervescence, and recovery of SpO 2 were observed in the combination group.","is_dataset_classified":null,"base_score":2.995732273553991,"endowment":2.995732273553991,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36610659","pmcid":"PMC9810545","openalex_id":"https://openalex.org/W4313594215","authors":[],"funders":[],"total_grants":0,"fwci":3.2133,"citation_percentile":0.92544959,"influential_citations":0,"citation_trend":[{"year":2023,"count":7},{"year":2024,"count":7},{"year":2025,"count":3},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"http://www.ijidonline.com/article/S1201971222006841/pdf","host_type":"journal"},{"url":"http://www.ijidonline.com/article/S1201971222006841/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1201971222006841?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1201971222006841?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ijid.2022.12.039","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36610659","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9810545","host_type":"repository"},{"url":"https://doaj.org/article/b44f924622ed47a1904be3da3e84d112","host_type":"repository"},{"url":"https://ora.ox.ac.uk/objects/uuid:7c1f90c8-1e1a-4240-9098-6201491c17e3","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9810545/pdf/main.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9810545","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9810545?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["COVID-19 Clinical Research Studies","SARS-CoV-2 and COVID-19 Research","Antibiotics Pharmacokinetics and Efficacy"],"mesh_terms":["COVID-19","SARS-CoV-2","Amides","Antiviral Agents","Benzamidines","Guanidines","Humans","Pyrazines","Single-Blind Method","Treatment Outcome","Disease Progression"],"keywords":["Favipiravir","Medicine","Confidence interval","Adverse effect","Randomized controlled trial","Pneumonia","Placebo","Internal medicine","Anesthesia","Coronavirus disease 2019 (COVID-19)","Disease","Nafamostat Mesilate","Covid-19","Sars-cov-2"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T20:52:12.840380Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}